Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant olaparib vs placebo in high-risk HER2-negative gBRCA1/2-mutated primary breast cancer
jRCT2080222553Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Jul 2014
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in breast cancer comparing Olaparib arm with Placebo arm (2 arms). Started Jul 2014; status: completed.
02
Drugs
olaparib
03
Conditions
breast cancer
Beyond the preview
Go deeper on jRCT2080222553.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222553.